CBS 2019
CBSMD教育中心
中 文

Scientific Library

Abstract

Recommended Article

Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function: Insights From EMPEROR-Reduced Incidence and Standardized Definitions of Mitral Valve Leaflet Adverse Events After Transcatheter Mitral Valve Repair: the EXPAND Study Longitudinal Change in Galectin-3 and Incident Cardiovascular Outcomes Prdm16 Deficiency Leads to Age-Dependent Cardiac Hypertrophy, Adverse Remodeling, Mitochondrial Dysfunction, and Heart Failure Lateral Wall Dysfunction Signals Onset of Progressive Heart Failure in Left Bundle Branch Block Long-term results after PCI of unprotected distal left main coronary artery stenosis: the Bifurcations Bad Krozingen (BBK)-Left Main Registry Long-Term Durability of Transcatheter Heart Valves: Insights From Bench Testing to 25 Years 2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes

Clinical Trial2021 Jan 26;143(4):310-321.

JOURNAL:Circulation. Article Link

Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function: Insights From EMPEROR-Reduced

F Zannad, JP Ferreira, SJ Pocock et al. Keywords: empagliflozin; glomerular filtration rate; heart failure; renal insufficiency; chronic

Full Text PDF